Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study-Reference-Cited by-同舟云学术

Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study

Published:2020-09 Issue:4 Volume:44 Page:609-618
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Petitdidier Nicolas,Beaugerie Laurent,Carbonnel Franck,Bourrier Anne,Treton Xavier,Rajca Sylvie,Malamut Georgia,Abitbol Vered,Allez Matthieu,Pelletier Anne-Laure,Marthey Lysiane,Jouet Pauline,Benamouzig Robert,Amiot Xavier^ORCID,Bouhnik Yoram,Amiot Aurelien^ORCID

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference39 articles.

1. Ulcerative colitis;Ungaro;Lancet,2017

2. Crohn's disease;Torres;Lancet,2017

3. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort;Gower-Rousseau;Gut,2017

4. Impact of treatment-related beliefs on medication adherence in immune-mediated inflammatory diseases: results of the Global ALIGN Study;Michetti;Adv Ther,2017

5. 3rd European evidence-based consensus on the diagnosis and management of Crohn's Disease 2016: part 1: diagnosis and medical management;Gomollón;J Crohns Colitis,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn’s disease;Scandinavian Journal of Gastroenterology;2023-11-22

3. Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis;Inflammatory Bowel Diseases;2022-11-01

4. Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases;Seminars in Arthritis and Rheumatism;2022-08